Clinical trial · Interventional
Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid
Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of GLIOPLAK is to evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. The studied parameter is the variation in platelet count during the radio-chemotherapy phase. The main objective is to identify early in Stupp protocol a group of patients having high risk to undergo thrombocytopenia in maintenance phase of temozolomide. With this result an algorithm of platelet monitoring for patients treated with Stupp protocol wil be proposed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Platelet level determination | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Stupp protocol
- description
- Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
- interventionNames
- Other: Platelet level determination
Primary outcomes (1)
- measure
- Number of time where platelet level was Under 100 000 per mm3
- timeFrame
- one year and 6 months
- description
- Determination of platelet level to predict the risk of thrombocytopenia
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age Superior to 18 years * Inform consent form signed * Newly diagnosed (histologically) glioblastoma * Stupp protocol treatment * with social insurance Exclusion Criteria: * Not inform consent form signed * participation to another clinical trial * other cancer * background of hematological pathology * patient under guardianship, curatorship
References
Publications (3)
- DERIVEDFontanilles M, Heisbourg JD, Daban A, Di Fiore F, Pepin LF, Marguet F, Langlois O, Alexandru C, Tennevet I, Ducatez F, Pilon C, Plichet T, Mokbel D, Lesueur C, Bekri S, Tebani A. Metabolic remodeling in glioblastoma: a longitudinal multi-omics study. Acta Neuropathol Commun. 2024 Oct 12;12(1):162. doi: 10.1186/s40478-024-01861-5. PMID 39394177
- DERIVEDDaban A, Beaussire-Trouvay L, Leveque E, Alexandru C, Tennevet I, Langlois O, Veresezan O, Marguet F, Clatot F, Di Fiore F, Sarafan-Vasseur N, Fontanilles M. Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients. Transl Oncol. 2024 Apr;42:101897. doi: 10.1016/j.tranon.2024.101897. Epub 2024 Feb 9. PMID 38340682
- DERIVEDFontanilles M, Marguet F, Beaussire L, Magne N, Pepin LF, Alexandru C, Tennevet I, Hanzen C, Langlois O, Jardin F, Laquerriere A, Sarafan-Vasseur N, Di Fiore F, Clatot F. Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. Acta Neuropathol Commun. 2020 Nov 4;8(1):179. doi: 10.1186/s40478-020-01057-7. PMID 33148330